FILE PHOTO: A robotic DNA sample automation machine works on DNA samples at a Regeneron Pharmaceuticals Inc. laboratory at the biotechnology company's headquarters in Tarrytown, New York, U.S., March 24, 2015. REUTERS/Mike Segar/File Photo U.S. sales of Regeneron's flagship eye drug, Eylea, increased 8 pct to $992 million in the second quarter, but missed estimates of $1 billion, according to brokerage Piper Jaffray.
https://www.reuters.com/article/us-regeneron-pharms-results/regeneron-profit-beats-expectations-on-sales-of-eczema-drug-idUSKBN1KN1I3
No comments:
Post a Comment